Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study

被引：26

作者：

Yoshikawa, Ayaka ^{[1
]}

Yoshida, Shuzo ^{[1
]}

Kimura, Yuko ^{[1
]}

Tokai, Nao ^{[1
]}

Fujiki, Yohei ^{[1
]}

Kotani, Takuya ^{[1
]}

Matsumura, Yoko ^{[1
]}

Takeuchi, Tohru ^{[1
]}

Makino, Shigeki ^{[1
]}

机构：

[1] Osaka Med Coll, Dept Internal Med 4, 2-7 Daigakumachi, Takatsuki, Osaka 5698686, Japan

来源：

MODERN RHEUMATOLOGY | 2018年 / 28卷 / 02期

关键词：

Biological disease-modifying antirheumatic drugs (bDMARDs); iguratimod; remission; rheumatoid arthritis; ultrasonography; KAPPA-B ACTIVATION; JAPANESE PATIENTS; PLUS METHOTREXATE; CYTOKINE PRODUCTION; ANTIRHEUMATIC DRUG; CLINICAL REMISSION; DISEASE-ACTIVITY; DOUBLE-BLIND; AGENT T-614; EFFICACY;

D O I：

10.1080/14397595.2017.1336865

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Objectives: In this study, iguratimod (IGU) was added to rheumatoid arthritis (RA) patients inadequately responding to 24-week or longer treatment with biological disease-modifying antirheumatic drug (bDMARDs), its effectiveness was assessed, and factors contributing to remission were evaluated.Methods: RA patients who fulfilled the following criteria were included: (i) 24-week of bDMARDs; (ii) 2.6<disease activity score (DAS) 28-erythrocyte sedimentation rate (ESR)<5.1 or the presence of synovitis with a power Doppler (PD) score 2 in at least 1 of the 28 joints on joint ultrasonography. Disease activity and joint ultrasound findings were evaluated at baseline and at 12 and 24weeks.Results: DAS assessing 28 joints with ESR (DAS28-ESR) decreased significantly from 3.450.92 at baseline to 2.85 +/- 1.13 at 24weeks (p<.001). Overall, 38.3% achieved clinical remission (c-remission). The total PD score decreased significantly from 8.7 +/- 6.1 at baseline to 5.5 +/- 5.0 at 24 weeks (p<.001). A lower baseline DAS28-ESR was related to c-remission after 24weeks (p =.002). Shorter duration of disease (p =.020) was related to ultrasound remission, in addition to a lower baseline DAS28-ESR (p<.001).Conclusions: IGU add-on therapy can be a therapeutic strategy to achieve remission in RA patients inadequately responding to 24-week treatment with bDMARDs.

引用

页码：227 / 234

页数：8

共 42 条

[1]

An anti-rheumatic agent T-614 inhibits NF-κB activation in LPS- and TNF-α-stimulated THP-1 cells without interfering with 1κBα degradation [J].

Aikawa, Y ;

Yamamoto, M ;

Yamamoto, T ;

Morimoto, K ;

Tanaka, K .

INFLAMMATION RESEARCH, 2002, 51 (04) :188-194

[2]

2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative [J].

Aletaha, Daniel ;

Neogi, Tuhina ;

Silman, Alan J. ;

Funovits, Julia ;

Felson, David T. ;

Bingham, Clifton O., III ;

Birnbaum, Neal S. ;

Burmester, Gerd R. ;

Bykerk, Vivian P. ;

Cohen, Marc D. ;

Combe, Bernard ;

Costenbader, Karen H. ;

Dougados, Maxime ;

Emery, Paul ;

Ferraccioli, Gianfranco ;

Hazes, Johanna M. W. ;

Hobbs, Kathryn ;

Huizinga, Tom W. J. ;

Kavanaugh, Arthur ;

Kay, Jonathan ;

Kvien, Tore K. ;

Laing, Timothy ;

Mease, Philip ;

Menard, Henri A. ;

Moreland, Larry W. ;

Naden, Raymond L. ;

Pincus, Theodore ;

Smolen, Josef S. ;

Stanislawska-Biernat, Ewa ;

Symmons, Deborah ;

Tak, Paul P. ;

Upchurch, Katherine S. ;

Vencovsky, Jiri ;

Wolfe, Frederick ;

Hawker, Gillian .

ARTHRITIS AND RHEUMATISM, 2010, 62 (09) :2569-2581

[3]

THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].

ARNETT, FC ;

EDWORTHY, SM ;

BLOCH, DA ;

MCSHANE, DJ ;

FRIES, JF ;

COOPER, NS ;

HEALEY, LA ;

KAPLAN, SR ;

LIANG, MH ;

LUTHRA, HS ;

MEDSGER, TA ;

MITCHELL, DM ;

NEUSTADT, DH ;

PINALS, RS ;

SCHALLER, JG ;

SHARP, JT ;

WILDER, RL ;

HUNDER, GG .

ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324

[4]

An Explanation for the Apparent Dissociation Between Clinical Remission and Continued Structural Deterioration in Rheumatoid Arthritis [J].

Brown, A. K. ;

Conaghan, P. G. ;

Karim, Z. ;

Quinn, M. A. ;

Ikeda, K. ;

Peterfy, C. G. ;

Hensor, E. ;

Wakefield, R. J. ;

O'Connor, P. J. ;

Emery, P. .

ARTHRITIS AND RHEUMATISM, 2008, 58 (10) :2958-2967

[5]

T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis [J].

Du, Fang ;

Lue, Liang-jing ;

Fu, Qiong ;

Dai, Min ;

Teng, Jia-lin ;

Fan, Wei ;

Chen, Shun-le ;

Ye, Ping ;

Shen, Nan ;

Huang, Xin-fang ;

Qian, Jie ;

Bao, Chun-de .

ARTHRITIS RESEARCH & THERAPY, 2008, 10 (06)

[6]

Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial [J].

Duan, Xin-Wang ;

Zhang, Xiu-Ling ;

Mao, Shao-Yuan ;

Shang, Jing-Jing ;

Shi, Xiao-Dong .

CLINICAL RHEUMATOLOGY, 2015, 34 (09) :1513-1519

[7]

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial [J].

Emery, P. ;

Keystone, E. ;

Tony, H. P. ;

Cantagrel, A. ;

van Vollenhoven, R. ;

Sanchez, A. ;

Alecock, E. ;

Lee, J. ;

Kremer, J. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) :1516-1523

[8]

Hara Masako, 2007, Mod Rheumatol, V17, P10

[9]

Hara Masako, 2007, Mod Rheumatol, V17, P1, DOI 10.1007/s10165-006-0542-y

[10]

Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: An open-label extension of a randomized, double-blind, placebo-controlled trial [J].

Hara, Masako ;

Ishiguro, Naoki ;

Katayama, Kou ;

Kondo, Masakazu ;

Sumida, Takayuki ;

Mimori, Tsuneyo ;

Soen, Satoshi ;

Nagai, Kota ;

Yamaguchi, Tomonobu ;

Yamamoto, Kazuhiko .

MODERN RHEUMATOLOGY, 2014, 24 (03) :410-418

← 1 2 3 4 5 →